58 results about "Angiogenesis Inhibition" patented technology

The invention relates to a high-performance angiogenesis inhibitor and a production method, which belongs to the field of the biological engineering pharmaceutical technology or protein polypeptide drugs. The invention designs a high-performance angiogenesis inhibitor RGD-ED with integrin compatibility, the inhibitor contains angiogenesis inhibition polypeptide isoleucine-valine-arginine-arginine-alanine-aspartate-arginine-alanine-alanine-valine-proline, and one or two ends of the inhibitor are respectively connected with polypeptides containing arginine-glycin-aspartate sequence. The RGD-ED of the invention can be synthesized. By the method of genetic engineering, the invention also expresses one of RGD-Eds in escherichia coli or other eukaryotic cells, and the RGD-ED is obtained by carrying out the separation, dissolution and renaturation of inclusion body protein and separation and purification by ion exchange chromatography. All the polypeptide sequences of the invention are modified by Polyethylene Glycol (PEG), heparin, dextran, polyvinylpyrrolidone (PVP), polyglycol-poly (amino acid) copolymer, palmitic acid, colominic acid and liposome, which includes liposome (REV), drying liposomal (DRV) and multivesicular liposome (Mvl). In vivo and in vitro experiments, the synthetic polypeptide sequence, product of genetic engineering and modified product of the invention can notably increase the effects of inhibiting the growth of endothelial cells, inhibiting angiogenesis and resisting tumor of the present angiogenesis inhibitors, and moreover, the high-performance angiogenesis inhibitor can be used as a drug curing solid tumors and rheumatoid arthritis.

The invention features methods and compositions for inhibiting angiogenesis in a tissue or detecting angiogenesis using antagonists of denatured or proteolyzed forms of laminin.

The invention provides a dimeric sesquiterpene compound, a preparation method thereof and the applications in aspects of angiogenesis inhibition, anti-prolyl endopeptidase, antibiosis, apastia and spice by using the compound as an active component.

The invention discloses a method for testing vascular endothelial inhibitor biological activity, the method utilizes vascular endothelial inhibitor standard and sample with the same concentration gradient after dilution in multiple proportions to inhibit HUVEC cell proliferation, and detects the proliferate inhibition activity of vascular endothelial inhibitor to HUVEC cells with trace enzyme reaction colorimetry, and then analyzes biological activity of angiogenesis inhibition of vascular endothelial inhibitor. The method uses the vascular endothelial inhibitor standard to correct testing errors of vascular endothelial inhibitor samples in different batches, which causes the cell proliferation inhibition activity testing results of vascular endothelial inhibitor have specificity and repeatability, and overcomes the defects that existed in prior vascular endothelial inhibitor activity testing method that the repeatability is bad, the method can not be unified, and the method can not meet the needs of large scale production and multiple-batch quality control.

Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.

The present invention discloses a Tat PTD-Endostatin recombination protein, which is a fusion protein comprising a protein transduction domain of human immunodeficiency virus (HIV) transactivation transduction protein Tat and human endostatin, wherein the amino acid sequence of the protein transduction domain of the HIV transactivation transduction protein Tat is represented by SEQ ID NO.1, and the amino acid sequence of the human endostatin is represented by SEQ ID NO.2. The protein of the present invention has the following advantages that: the function of the endostatin can be maintained, wherein the function of the endostatin is that the endostatin can inhibit angiogenesis; the protein has advantages of high transduction efficiency, easy blood-brain barrier crossing, and easy blood-ocular barrier crossing; the protein can overcome the limitation of the poor membrane spanning effect of the endostatin and play the angiogenesis inhibition effect well; the protein can be used for treatments of various diseases caused by angiogenesis, including ocular vascular proliferative diseases and various tumors, such as diabetes retinopathy, non-small cell lung cancer, and the like.

A novel fusion protein, comprising a receptor-antagonizing domain and an angiogensis inhibiting domain, characterized, for example, by its ability to block apoptosis and / or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.

The present disclosure relates to a recombinant adenovirus with improved angiogenesis inhibition activity and a pharmaceutical composition for inhibiting angiogenesis. The recombinant adenovirus includes: (a) an inverted terminal repeat (ITR) nucleotide sequence of an adenovirus; and (b) a nucleotide sequence coding for a chimeric decoy receptor containing (i) an extracellular domain of vascular endothelial growth factor receptor 1 (VEGFR-1) and (ii) an extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2). The recombinant adenovirus according the present disclosure which expresses the chimeric decoy receptor inhibits angiogenesis very effectively and can be used for gene therapy for various angiogenesis-related diseases. Particularly, the recombinant adenovirus of the present disclosure has superior oncolytic activity.

The present invention relates to a fumagillol derivative and the pharmaceutically acceptable salt thereof, and a method for preparing the compound. The compound of the invention can be prepared by acidylation, hydrolyzation and alkylation. The compound of the invention can be prepared to the form of pharmaceutically acceptable salt or inclusion compound. Comparing with the conventional angiogenesis inhibitor, the fumagillol derivative provided with the invention has more excellent angiogenesis inhibition function, low toxicity, excellent dissolvability and chemical stability. The compound of the invention can be used as anticancer medicine, cancerometastasis restrainer, or the remedy for treating the rheumatoid arthritis, psoriasis, diabetic retinopathy or adiposis.

Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.

The invention discloses application of TTR (transthyretin) to angiogenesis inhibition, and belongs to the fields of biochemistry, molecular biology and medicine. After the TTR is given to mammals, inSTZ induced diabetes rat and mouse models, the new vessels of eyes are obviously reduced. Tumor new vessel, diabetes new vessel, eye new vessel and brain new vessel in vitro experiment models verify that the TTR has the effect of inhibiting the angiogenesis; the result shows that the TTR can act on an in vitro cell model in anoxic environment of brain and can continuously and efficiently inhibit the generation of new vessels. When the TTR acts on endothelial cells of umbilical veins, the formation of 90 percent of vessels can be obviously inhibited; when the TTR acts on endothelial cells of cerebral microvessel, the formation of 95 percent of vessels can be effectively inhibited; when the TTR acts on the endothelial cells of eye microvessel, the formation of 90 percent of vessels can be effectively inhibited; when the TTR acts on rat and mouse models, the as high as generation of 90 percent of new vessels can be effectively inhibited.

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

The present invention provides a preparation method of angiogenesis inhibitory factor. Dasyatis cartilage is firstly crashed, then extracted, roughly separated and purified, finally desalinated, frozen and dried, thus obtaining the dasyatis cartilage angiogenesis inhibitory factor, shortened as DCAIF-I; wherein, the purification adopts Hitrap DEAEFF ion-exchange column chromatography, Superdex 75 10 / 300 GL ion-exchange column chromatography and Shim-packVP-ODS HPLC ion-exchange column chromatography. The preparation method of angiogenesis inhibitory factor provided by the present invention provides a method of extracting the angiogenesis inhibitory factor from the dasyatis cartilage. Through experiment, the DCAIF-I obtained in the method can effectively inhibit the angiogenesis and has a certain concentration dependence. The preparation method is a method in which the angiogenesis inhibitory factor can be effectively and optimally distilled from the dasyatis cartilage.

The invention discloses application of circRNA in the field of angiogenesis inhibition, and belongs to the fields of biochemistry, molecular biology and medicine. The invention discovers that hsa_circ_0007411 can continuously act on eye vascular endothelial cells, change the structure of angiogenesis and inhibit angiogenesis. By applying the hsa_circ_0007411 to the eye microvascular endothelial cells, 90 percent of angiogenesis can be effectively inhibited, and angiogenesis of neovascularization-related diseases can be effectively inhibited. The effect of hsa_circ_0007411 on cell proliferationand migration is verified, thereby proving that hsa_circ_0007411 can remarkably inhibit cell proliferation and migration, has a remarkable inhibition effect on the proliferation of endothelial cells,and has important guiding significance for diseases related to the proliferation of vascular endothelial cells.

The invention relates to medicinal application of microcystic toxins-LR, in particular to application of the microcystic toxins-LR in preparation of medicines for preventing and treating pulmonary fibrosis, belonging to the technical field of medicines. The microcystic toxins-LR is proved to be capable of improving the state of pulmonary fibrosis caused by bleomycin. The microcystic toxins-LR can inhibit the mRNA expression rise, caused by the bleomycin, of pulmonary fibrosis-related molecules such as transforming growth factor (TGF)-beta, tumor necrosis factor (TNF)-alpha, IL-1beta, IL-6, NF-kB and ET-1. The microcystic toxins-LR can inhibit the mRNA expression rise, caused by the bleomycin, of lung tissue vascular endothelial growth factor (VEGF). The microcystic toxins-LR interferes and relieves rat pulmonary fibrosis, induced by the bleomycin, by using ways such as a TGF-beta / Smad pathway and angiogenesis inhibition. A new way is provided for preparing the medicines for preventing and / or treating the pulmonary fibrosis disease.

The invention discloses an application of a compound IC-4 with the structural formula represented by formula (I) or its salts in antiangiogenesis, and further discloses an application of the compound IC-4 with the structural formula represented by formula (I) or its salt in preparation of antiangiogenic agents. Researches on the application of the IC-4 or its salt in the antiangiogenesis are based on researches on growth factor induced endothelial cell growth inhibition, angiogenesis inhibition, endothelial cell migration inhibition and endothelial cell transfer inhibition of the IC-4 or its salts, and combine with a scientific and reasonable research system constructed through integral experiments of zebra fish embryo angiogenesis.

The invention relates to compositions and methods useful in treating or preventing angiogenic disease. The invention provides for compositions comprising cephalotaxine alkaloids as antiangiogenic agents for treatment of a host with an angiogenic disease or for prophylactic treatment of a host to inhibit the onset or progression of an angiogenic disease.

A treatment for cancer is provided. The treatment may include administering a therapeutic amount of L-histidine, D-cycloserine, quisqualic acid or suramin or analogs thereof.

Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL or FL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and is most preferably an immunological treatment and comprises the administration of an antibody to the patient.

In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.

Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL or FL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and is most preferably an immunological treatment and comprises the administration of an antibody to the patient.

The invention discloses'applications of an artificially synthesized gene-derived recombinant protein rLj-RGD4 in anti-tumor drugs', belonging to the field of biotechnology and relating to gene cloning and protein expression of an artificially synthesized gene lj-rgd4, dose-dependent potent angiogenesis inhibition and tumor inhibition functions of the recombinant protein rLj-RGD4, and applications of the recombinant protein in the antitumor drugs as an angiogenesis inhibitor.

A DNA composition effective for inhibiting endothelial cell proliferation comprises a DNA construct operably encoding a vascular endothelial growth factor (VEGF) receptor polypeptide, which can be a full length VEGF receptor protein or an immunogenic fragment thereof. This invention provides DNA compositions that encode VEGF receptor-2 (KDR), VEGF receptor-1 (Flt-1), or Flk-1 (the murine homolog of KDR), as well as methods of using such a DNA composition to inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved.

The invention provides an intravenous injection drug-loading targeting nano-carrier for RA (Rheumatoid Arthritis) and a preparation method of the drug-loading targeting nano-carrier. According to the technical scheme, for final effector cells FLSs of RA, PCADK with a pH controlled release function is used as a main skeleton; PEI is added to modify and wrap NK4 to improve nucleic acid stability; then, VIP is added to carry out active targeting regulation and control; a novel multifunctional drug-loading targeting nano-carrier for intravenous injection is constructed step by step; acid sensitive release is responded; therefore, the FLSs can be efficiently delivered to the RA focus; and the optimal anti-RA curative effects of extracellular inhibition of angiogenesis, intracellular killing of malignant hyperplasia FLSs and remodeling of the immune microenvironment of the RA focus are achieved. According to the invention, the PCADK composite nanomaterial is prepared based on an emulsion method; and experimental results show that: the particle size of the obtained PCADK composite nanomaterial is at the nanometer level, the Zeta potential is particles with positive electricity, the morphology is good, and the PCADK composite nanomaterial is expected to serve as a brand new targeted drug to be used for clinical treatment of RA.

The invention relates to a composition for angiogenesis inhibition comprising a peroxidasin inhibitor as an effective ingredient, and more particularly, to a method of screening angiogenesis inhibitor, which includes steps of treating a test agent, and analyzing peroxidasin gene expression or protein activity, and comparing peroxidasin gene expression or protein activity between a case treated with the test agent and a case not treated with the test agent. Accordingly, since the inhibitor of the peroxidasin expression or protein activity according to the present invention can effectively inhibit migration, proliferation and tube formation of endothelial cells, the inhibitor can be effectively used for preventing or treating a variety of diseases or conditions of the diseases derived from abnormal regulation of angiogenesis.

The invention relates to an angiogenesis inhibition drug. The angiogenesis inhibition drug has a structural formula shown in the following description. A result of a research on zebrafish embryonic development shows that the angiogenesis inhibition compound belongs to a Src kinase inhibitor, through VEGFR2 and MAP kinase approach inhibition, vascular endothelial cell integrity is interfered so that small blood vessel lumen diameters are gradually reduced and blood vessel endothelium is broken finally and thus the angiogenesis inhibition drug belongs to an angiogenesis inhibition compound.

A method of inhibiting angiogenesis by applying a protein polysaccharide of a (1→6)-β-D-glucan with a glucan:protein ratio of 55:43 [w / w], obtained by extracting with a 5 w % aqueous solution of sodium hydroxide a residue of extraction and removal of water-soluble polysaccharides from the Agaricus blazei Murill (himematsutake) fruiting body, and a food / beverage composition for angiogenesis inhibition containing the protein polysaccharide of (1→6)-β-D-glucan.

The present invention relates to a composition for use in prevention or treatment of a vascular-related disease, particularly used for angiogenesis inhibition, tumor growth inhibition or tumor metastasis inhibition, or immunostimulation, which comprises glutamic acid or derivatives thereof, preferably glutamic acid is anhydrous glutamic acid represented by Formula (1) or pyroglutamic acid, and a pharmaceutically acceptable carrier or an edible carrier, and a method of preventing or treating a vascular-related disease.

The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and / or the intracellular signaling from TRPV4 via β1 integrin activation.

The present invention discloses a halogen or nitrogen-containing group substituted bibenzyl analog or a pharmaceutically acceptable salt, a hydrate thereof, wherein the halogen or nitrogen-containing group substituted bibenzyl analog is represented by a formula I, and A is halogen or nitrogen-containing group substituted phenyl or a 5-membered or 6-membered unsaturated nitrogen-containing heterocyclic ring containing 1-2 N atoms. The present invention further discloses a preparation method of the halogen or nitrogen-containing group substituted bibenzyl analog, and applications of the halogen or nitrogen-containing group substituted bibenzyl analog or the pharmaceutically acceptable salt and the hydrate thereof in preparation of tumor treating drugs and angiogenesis inhibition drugs. According to the present invention, the novel-structure bibenzyl analog is synthesized through the seven-step reaction, such that the reaction steps are simple, the conditions are mild, the yield is high, and the total yield is 32-51%; the bibenzyl analog provides different degrees of activities in preparation of tumor resistance and angiogenesis inhibition; and the important significance is provided for preparation of the tumor inhibition drugs and the angiogenesis inhibition drugs. The formula I is defined in the specification.